Latest research
Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Top papers this month · This week's roundup
Trending topics
In 14,810 high-risk patients with atrial fibrillation, asundexian 50 mg daily gave more stroke or systemic embolism than apixaban (1.3% vs 0.4%; HR 3.79) in a trial stopped early, though major bleeding was lower (0.2% vs 0.7%; HR 0.32).
Clinical trialn = 14,810
Piccini et al. Asundexian versus Apixaban in Patients with Atrial Fibrillation